Navigation Links
BD Announces Results For 2011 First Fiscal Quarter
Date:2/7/2011

guidance, resulted from certain first quarter events, including the retroactive extension of the U.S. research tax credit.

Segment ResultsIn the BD Medical segment, worldwide revenues for the quarter were $927 million, representing a decrease of 4.5 percent compared with the prior-year period, or a decrease of 4.3 percent on a foreign currency-neutral basis. The segment's revenue decline reflects an unfavorable comparison to the prior year of about 6 percentage points due to strong sales related to the H1N1 flu pandemic in fiscal year 2010, partially offset by solid growth in the Diabetes Care unit with particularly strong growth in pen needles.

In the BD Diagnostics segment, worldwide revenues for the quarter were $602 million, representing an increase of 1.0 percent compared with the prior-year period, or 0.6 percent on a foreign currency-neutral basis.  Segment revenue growth was negatively impacted by about 2 percentage points due to strong sales related to the flu pandemic in fiscal year 2010.  The segment growth was primarily driven by strong sales in Preanalytical Systems safety-engineered products, and Women's Health and Cancer in the Diagnostic Systems unit.

In the BD Biosciences segment, worldwide revenues for the quarter were $314 million, representing an increase of 3.7 percent compared with the prior-year period, or 3.5 percent on a foreign currency-neutral basis.  Segment revenue growth was negatively impacted by about 2 percentage points due to strong sales related to stimulus spending in the U.S. in fiscal year 2010.  Segment growth was primarily driven by instrument and reagent sales in the Cell Analysis unit.

Geographic ResultsFirst quarter revenues in the U.S. were $829 million, representing a decrease of 2.9 percent compared with the prior-year period, including a negative impact of 6.0 percentage points due to flu pandemic-related sales in fiscal year 2010.  Revenues outside of the U.
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
2. BD Announces Agreement to Acquire Accuri Cytometers, Inc.
3. Misonix Announces Completion of Product Registrations in Key Latin American Markets
4. ConvaTec Announces New Appointments to Leadership Team
5. Medivation Announces Participation in 13th Annual BIO CEO & Investor Conference
6. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
7. Fairleigh Dickinson University Announces Partnership with Medco Health Solutions, Inc. for New School of Pharmacy
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
9. Dendreon Announces Exercise and Closing of Overallotment Option
10. Hospira Announces FDA Approval of Topotecan Injection
11. BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
(Date:9/2/2015)... -- Elekta, a global cancer management company, will ... 6:30-8:30 p.m., at Elekta,s North American headquarters in ... will feature Professional BMX athlete, Josh Perry , who ... Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain disorders. ... diagnosed in Georgia in 2015 and ...
(Date:9/2/2015)... Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) ... to implement a buccal cannabis co-development arrangement ... has been formalized. Generex and ... and Technology Licensing Agreement.  Pursuant to the ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3
... , , INDIANAPOLIS, Nov. 16 ... Chairman, President and Chief Executive Officer John Lechleiter today presented ... check represents the contributions of Lilly,s U.S. employees and retirees ... funds were raised for the Central Indiana chapter and other ...
... , - Used during coronary angioplasty plus stenting, in ... new reversible blood thinner did not have a significantly ... all-cause mortality, heart attack and need for new procedures ... drug significantly lessened the risk for two pre-specified single ...
Cached Medicine Technology:Lilly Surpasses United Way 2009 Campaign Goal 2Lilly Surpasses United Way 2009 Campaign Goal 3American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... investment, announced the two leaders who will deliver keynote presentations at the upcoming ... the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of Optum, will ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Blincyto® (blinatumomab) – in the news recently following a decision by the Centers ... patients – is likely to average approximately $71,000 or roughly 40% of its ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Officer following the departure of Kristen Dietz, former Chief Operations Officer. Shaun ... the following statement welcoming Mr. Salot: “ Stanley H. Salot Jr , our ...
(Date:9/2/2015)... ... 2015 , ... Good health and a good cause paired up at The ... BCBSNJ) donated $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. ... The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... at Children's Healthcare of Atlanta to help support childhood cancer research. On ... upcoming WSB Radio Care-A-Thon , which is the fund-raising event DoMyOwnPestControl.com sponsors ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:Healtec® Announces Executive Leadership Change 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2
... a gene that appears to increase a person,s risk ... of the disease. The gene, abbreviated as MTHFD1L, is ... association study. Details are published September 23 in the ... of researchers was led by Margaret A. Pericak-Vance, PhD, ...
... of motorcycle crashes were 1.5 times more likely to ... though many more of the African-American victims were wearing ... new study by Johns Hopkins researchers. Results of ... August issue of the American Journal of Surgery ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. 23 ... use and texting soared in the space of three years, ... alone caused more than 16,000 deaths in car accidents from ... cell phones and texting while driving rose 28 percent in ...
... Cancer Center have discovered a new cell signaling pathway ... when defective, helps promote the formation of several major ... The new pathway, part of a global DNA damage ... are known to cause cancer because, unchecked, they can ...
... Nursing professor, Dr. Diane Doran, was awarded more than ... safety of over 900,000 Canadians who receive health care ... Patient Safety Institute and its partners announced today the ... of Canada,s leading healthcare researchers. The selected research team ...
... a well-crafted football play designed to block the opposing ... constantly executes complex ,plays, or sequences of events to ... Scientists at the University of Rochester Medical Center recently ... the unwanted enlargement of the heart and a well-known ...
Cached Medicine News:Health News:Team of researchers finds possible new genetic risk for Alzheimer's disease 2Health News:Black motorcyclists -- even in helmets -- more likely to die in crashes 2Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Molecular 'playbook' for halting heart failure risk factor uncovered 2
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, ... its space saving, 2-level design. Up to 27 ... to give you the flexibility to tailor your ... lab. Two start stations allow for continuous loading; ...
... latest from the leader in automatic slide ... modern approach to slide staining, ending messy ... blood smears, bone marrow and other body ... Aerospray stainer becomes a superb cytocentrifuge with ...
Medicine Products: